Clinical Trial

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Study acronym: ACADIA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Protocol Amendment History 4 changes
notable Trial sites expanded: 144 -> 150 locations 2026-08-14
notable Trial sites expanded: 140 -> 144 locations 2026-07-15
notable Trial sites expanded: 135 -> 140 locations 2026-06-05
notable Trial sites expanded: 131 -> 135 locations 2026-05-02
Trial Details
NCT Number NCT06307665
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Asthma
Enrollment 440 participants
Start Date 2024-05-20
Primary Completion 2027-10-13 (estimated)
Study Completion 2027-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-13